HARMONi-7 Phase 3 Clinical Trial
1L Metastatic NSCLC
NCT06767514: Click to view on ClinicalTrials.gov
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (TPS ≥ 50%)
HARMONi-7 Study Design
Monotherapy Ivonescimab vs. Pembrolizumab
Abbreviations: NSCLC, non-small cell lung cancer; PD-L1, programmed cell death-ligand 1; Q3W, every three weeks; PFS, progression free survival; OS, overall survival; ORR, overall response rate; 1L, first-line, TPS, Tumor Proportion Score
Ivonescimab is an investigational therapy that is not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).
For additional information on the HARMONi-7 Clinical Trial, please contact medinfo@smmttx.com
